Granules India's Gagillapur Facility Completes US FDA Inspection with Six Observations

Granules India Limited, announced the completion of the US Food and Drug Administration (USFDA) inspection at its Gagillapur facility in Hyderabad, Telangana. The inspection, conducted from 26th August to 6th September 2024, concluded with six observations.

The recent inspection covered both Current Good Manufacturing Practice (cGMP) and Pre-Approval Inspection (PAI) processes. Granules India is committed to addressing the observations promptly and will submit its response to the USFDA within the stipulated timeframe. The Gagillapur facility continues to play a vital role in the company's global operations, ensuring the supply of high-quality pharmaceutical products to markets worldwide.

Shares of Granules India Limited was last trading in BSE at Rs. 687.85 as compared to the previous close of Rs. 697.80. The total number of shares traded during the day was 39769 in over 2583 trades.

The stock hit an intraday high of Rs. 708.40 and intraday low of 684.35. The net turnover during the day was Rs. 27729424.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 GagillapurFacility Hyderabad USFDA Inspection 6Observation cGMP PAI